Bank of America has published a research report on Ironwood Pharmaceuticals IRWD that maintained its Neutral rating and raised the price target from $15 to $18 due to positive prescription data.
In the report Bank of America said, "As a reminder, we had previously lowered our Linzess sales estimates significantly because initial January prescription trends were slower than we had anticipated; following additional data in February however, trends have improved, suggesting the heavy initial sampling period has been effective in converting to paid prescriptions."
Ironwood Pharmaceuticals closed Monday at $17.18.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in